IP Library Granted Patent US 9,006,212
Granted Patent B2
US 9,006,212 · App. 12/778,077 · Granted Apr 14, 2015

Compositions and methods for pest control

Inventors: Ido Bachelet (Brookline, MA); Ram Sasisekharan (Bedford, MA); Mark Bulmer (Towson, MD); Rebeca B. Rosengaus (Boston, MA)
Assignees: Massachusetts Institute of Technology; Northeastern University
C12Q1/34A01N43/16C08B37/0024G01N2333/43552G01N2333/43582G01N2333/924
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,006,212
App. No.
12/778,077
Granted
Apr 14, 2015
Kind
B2
Abstract

Provided herein are compositions and kits comprising carbohydrate-based inhibitors that bind GNBP and/or inhibit β(1,3)-glucanase activity. Also provided are methods of using such inhibitors to protect against or treat pest infestation, as are compositions and kits comprising subparts of the carbohydrate-based inhibitors.

Claims (37)

1. A method for providing protection against or treating a pest infestation consisting of:

contacting a pest, soil, wood, plant, seeds, grain or manmade structure with a carbohydrate-based inhibitor that inhibits β(1,3)-glucanase activity of gram-negative bacteria binding protein (GNBP) in an amount effective to protect against or to treat the pest infestation,

wherein the carbohydrate-based inhibitor does not inhibit cellulase or stimulate feeding in the pests of the pest infestation.

2. The method of claim 1 , wherein the carbohydrate-based inhibitor does not inhibit α and/or β-1,4-glucosidase in the pests of the pest infestation.

3. The method of claim 1 , wherein carbohydrate-based inhibitor inhibits β(1,3)-glucanase activity and not the activity of another glucanase and/or glucosidase in the pests of the pest infestation.

4. The method of claim 1 , wherein the carbohydrate-based inhibitor is not gluconolactone.

5. The method of claim 1 , wherein the carbohydrate-based inhibitor comprises a β(1,3) glycosidic linkage at a reducing end.

6. The method of claim 1 , wherein the carbohydrate-based inhibitor is conjugated to a nanoparticle.

7. The method of claim 1 , wherein the carbohydrate-based inhibitor is conjugated to a dendrimer.

8. The method of claim 1 , wherein the carbohydrate-based inhibitor is conjugated to polyacrylamide.

9. The method of claim 1 , wherein the carbohydrate-based inhibitor is a di/tri/tetrameric β(1,3)-D-glucan derivative or a di/tri/tetrameric β(1,3)-L-glucan derivative.

10. The method of claim 9 , wherein the di/tri/tetrameric β(1,3)-D-glucan derivative or di/tri/tetrameric β(1,3)-L-glucan derivative is D-Glc-β(1,3)-D-glucono-Δ-lactone, D-Glc-β(1,3)-D-Glc-β(1,3)-D-Glc-β(1,3)-D-glucono-Δ-lactone, L-Glc-β(1,3)-L-glucono-Δ-lactone or L-Glc-β(1,3)-L-Glc-β(1,3)-L-Glc-β(1,3)-L-glucono-Δ-lactone.

11. The method of claim 1 , wherein the carbohydrate-based inhibitor is a β(1,3)-D-glucan-LPS (lipopolysaccharide) conjugate or a β(1,3)-L-glucan-LPS conjugate.

12. The method of claim 11 , wherein the β(1,3)-D-glucan-LPS conjugate is eritoran-D-glucono-Δ-lactone.

13. The method of claim 11 , wherein the β(1,3)-L-glucan-LPS conjugate is eritoran-L-glucono-Δ-lactone.

14. The method of claim 11 , wherein the β(1,3)-D-glucan or β(1,3)-L-glucan is conjugated to the LPS with an acyl spacer.

15. The method of claim 11 , wherein the β(1,3)-D-glucan or β(1,3)-L-glucan is conjugated to the LPS with a heterobifunctional cross-linker.

16. The method of claim 1 , wherein the carbohydrate-based inhibitor is a polyvalent D-glucono-D-lactone-LPS conjugate or a polyvalent L-glucono-L-lactone-LPS conjugate.

17. The method of claim 16 , wherein the polyvalent D-glucono-D-lactone-LPS conjugate or a polyvalent L-glucono-L-lactone-LPS conjugate is conjugated to a nanoparticle.

18. The method of claim 16 , wherein the polyvalent D-glucono-D-lactone-LPS conjugate or a polyvalent L-glucono-L-lactone-LPS conjugate is conjugated to a dendrimer.

19. The method of claim 16 , wherein the polyvalent D-glucono-D-lactone-LPS conjugate or a polyvalent L-glucono-L-lactone-LPS conjugate is conjugated to polyacrylamide.

20. The method of claim 16 , wherein the polyvalent D-glucono-D-lactone or polyvalent L-glucono-L-lactone is D-δ-gluconolactone (GDL).

21. The method of claim 16 , wherein the LPS is eritoran.

22. The method of claim 1 , wherein the GNBP is GNBP-1 or GNBP-2.

23. The method of claim 22 , wherein the GNBP is GNBP-2.

24. The method of claim 1 , wherein the pest infestation is an insect infestation.

25. The method of claim 1 , wherein the pest infestation is a plant pest infestation.

26. The method of claim 1 , wherein the pest infestation is a/an termite, fly, moth, ant, beetle, mosquito, silk worm, locust or cockroach infestation.

27. The method of claim 26 , wherein the pest infestation is a termite infestation.

28. The method of claim 27 , wherein the termites of the termite infestation are of the N. corniger, Z. augusticollis, C. secundus, R. virginicus or R. flavipes species.

29. The method of claim 1 , wherein the contacting comprises applying or spraying the carbohydrate-based inhibitor onto the pest, soil, wood, plant, seeds, grain or manmade structure.

30. The method of claim 1 , wherein the contacting comprises soaking the pest, soil, wood, plant, seeds, grain or manmade structure with the carbohydrate-based inhibitor.

31. The method of claim 1 , wherein the contacting comprises incorporating or impregnating the carbohydrate-based inhibitor into the pest, soil, wood, plant, seeds, grain or manmade structure.

32. The method of claim 1 , wherein the method further comprises contacting the pest, soil, wood, plant, seeds, grain or manmade structure with another pesticide.

33. The method of claim 32 , wherein the other pesticide is an insecticide, fungicide or a herbicide.

34. The method of claim 1 , wherein the carbohydrate-based inhibitor is in an aqueous composition.

35. The method of claim 1 , wherein the carbohydrate-based inhibitor is in a dry formulation.

Assignments (4)
CONFIRMATORY LICENSE Recorded Feb 17, 2024
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 066486/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2010
From: ROSENGAUS, REBECA B.; BULMER, MARK
To: NORTHEASTERN UNIVERSITY
Reel/Frame 024835/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2010
From: BACHELET, IDO; SASISEKHARAN, RAM
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 024835/0547 →
CONFIRMATORY LICENSE Recorded Aug 3, 2010
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024778/0620 →
Continuity (2)
Provisional Application 61215883 · May 11, 2009
Related Publication 20100317614A1 · Dec 16, 2010